Pelvic mass in a young woman with a background of ovarian dysgerminoma: differential diagnosis

Vale-Fernandes, Emídio; Rodrigues, Fedra; Monteiro, Camila Nascimento; Serrano, Paula

doi:10.1136/bcr-2015-212550

Cited by 2 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patterns of growth present as solid, trabecular, insular, pseudoglandular and individually arranged cells separated by fibrous septa with infiltration of cytotoxic lymphocytes and epitheloid histiocytes, often with tumor invasion (Fig. 2) [28,29]. About 5% of DYS show syncytiotrophoblastic cells, mostly with elevation of ß-human chorion gonadotropin (ß-HCG) serum levels.…”

Section: Pathologymentioning

confidence: 99%

Management of malignant dysgerminoma of the ovary

Arndt¹,

Taube²,

Deubzer³

et al. 2022

EJGO

View full text Add to dashboard Cite

The evolution of treatment for malignant ovarian germ cell tumors has been one of the most successful in the history of gynecologic oncology, with dysgerminoma as the most common type of malignant ovarian germ cell tumors. Since the introduction of platinumbased chemotherapy in the 1980s, 5-year survival rates for early-stage dysgerminomas have been close to 100%, and as high as 98% for advanced stages. Despite this remarkable achievement, many questions remain in routine treatment. By performing a literature review, we aim to highlight both the current treatment of malignant dysgerminoma and unanswered questions in the modern management of this disease. These issues relate firstly to surgical therapy, such as the role of routine omentectomy and lymphadenectomy, the value of complete surgical resection, and the possibility of fertility-sparing surgery. Second, chemotherapy and the question of the possibility of de-escalation in early stages and the potential of neoadjuvant chemotherapy in advanced stages will be addressed. Finally, a brief overview of the current developments of new drug treatment regimens will be given.

show abstract

Section: Pathologymentioning

confidence: 99%

Management of malignant dysgerminoma of the ovary

Arndt¹,

Taube²,

Deubzer³

et al. 2022

EJGO

View full text Add to dashboard Cite

show abstract

“…About 5-15% of patients have bilateral ovarian involvement and few present lymph node metastases and/or peritoneal involvement. However, prognosis in these groups is well with 85% five-year survival after appropriate chemotherapy (6,10).…”

Section: Introductionmentioning

confidence: 99%

“…The foci of necrosis, hemorrhage and cystic degeneration may be present but suggest the possibility of other neoplastic germ cell elements (6,7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pseudopapillary and Macrofollicular Microscopic Growth Patterns in an Advanced Stage Ovarian Dysgerminoma: A Case Report

2018

View full text Add to dashboard Cite

KEYWORDS ABSTRACT DysgerminomaMicroscopic Growth Pattern Pseudopapillary Macrofollicular Dysgerminoma is one of the two most common types of ovarian germ cell tumors. Providing accurate pathologic diagnosis and treatment planning, the prognosis is good even in advanced stages. Pathologic diagnosis is generally straightforward. In microscopic examination, the usual known growth patterns in tumor cells are solid, trabecular, insular and rarely pseudoglandular.In this paper, we reported an advanced ovarian dysgerminoma with different microscopic patterns of growth, including pseudopapillary and macrofollicular structures, in an 18-year-old woman. The patient underwent staging laparotomy and is currently receiving chemotherapy. Article Info

show abstract

Pelvic mass in a young woman with a background of ovarian dysgerminoma: differential diagnosis

Cited by 2 publications

References 4 publications

Management of malignant dysgerminoma of the ovary

Management of malignant dysgerminoma of the ovary

Pseudopapillary and Macrofollicular Microscopic Growth Patterns in an Advanced Stage Ovarian Dysgerminoma: A Case Report

Contact Info

Product

Resources

About